Print this page

Calendar of Events - Network at Our Friendly Meetings

LES Benelux Topic meeting

11 October 2012 08:30 to 16:45

Influence of Intellectual Property in health development; a barrier or an incentive?


11th October 2012

Colonster Castle of the Sart Tilman University Campus, Liege, Belgium

In our countries, Intellectual Property(IP) is generally viewed as an incentive for the pharmaceutical industry to develop new drugs. This helps to guarantee safe and effective pharmaceuticals and to guard against low quality or even dangerous copies. However, what does it mean to companies wishing to commercialize generics?

Does an SME or a spin-off intending to develop a molecule need IP to mobilize the necessary funds? In the case of neglected or rare diseases, is IP a barrier or an incentive? How can an ‘orphan drug designation’ be used to obtain adequate return on investment? How to manage IP effectively and what licensing practices facilitate access to medicines for developing countries? How does the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) contribute to public health?


Registration Form